Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Q2 2024 Earnings Presentation
28 slides from Nykode Therapeutics Asa's earnings presentation, Aug 21, 2024
Slide 1: Q2 2024 Results Presentation
Q2 2024 Results Presentation August 21, 2024
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Today's presenters from Nykode management
Today’s presenters from Nykode management International management team with solid drug development experience MICHAEL ENGSIG AGNETE FREDRIKSEN HARALD GURVIN KLAUS EDVARDSEN Chief Executive Officer Chief Scientific Officer & Chief Financial Officer Chief Research & Business Development Development O
Slide 4: Q2 2024 Highlights
Q2 2024 Highlights • Strategic repositioning of VB10.16 to focus the development on locally advanced cervical cancer and recurrent metastatic head and neck cancer (post-period end). • Discontinuation of the VB-C-04 trial (post-period end). • Announced clinical collaboration with MSD to evaluate VB10
Slide 5: Broad pipeline targeting early to late-stage cancer treatment
Broad pipeline targeting early to late-stage cancer treatment Upcoming Asset Indication Rights Preclinical Phase 1 Phase 2 Phase 3 Catalyst Oncology 1 HPV16+ cervical cancer C-02 Publication of final data 2 Dose level HPV16+ head and neck cancer C-03 recommendation VB10.16 (2H 2024) Off-the-shelf 2
Slide 6: R&D update
R&D update Nykode Therapeutics | Q2 '24 webcast | Non-confidential 6
Slide 7: Strategic repositioning of VB10.16
Strategic repositioning of VB10.16 • Strategic repositioning of VB10.16 to focus the development on locally advanced cervical cancer and recurrent metastatic head and neck cancer. • Discontinuation of the VB-C-04 trial. • C-04 initially expected to provide a fast-to-market path for VB10.16. • Full F
Slide 8: Data from C-02 supports our efforts in locally advanced settings
Data from C-02 supports our efforts in locally advanced settings • Supports deepening responses in combination with an CPI. • Demonstrated capacity to maintain clinical benefit irrespective of degree of disease control. • Final clinical data to be presented in a future scientific publication. Nykode
Slide 9: VB-C-05 locally advanced cervical cancer
VB-C-05 locally advanced cervical cancer • Clinical collaboration with MSD to evaluate VB10.16 in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive high-risk locally advanced cervical cancer • Incorporate VB10.16 into the existing treatment Clinical collaboration regimen of
Slide 10: VB10.NEO Individualized cancer immunotherapy
VB10.NEO Individualized cancer immunotherapy Nykode Therapeutics | Q2 '24 webcast | Non-confidential 10
Slide 11: Nykode's individualized cancer vaccine is designed to target a broad range of tumours
Nykode’s individualized cancer vaccine is designed to target a broad range of tumours Vaccine design Key clinical results • APC-targeted vaccine technology leverages targeting unit to enhance CD8+ response ♦ 2 clinical trials in more • Induces immune response in hard-to-treat patients with low TMB t
Slide 12: New Patent Granted for VB10.NEO
New Patent Granted for VB10.NEO • VB10.NEO: Nykode’s fully individualized neoantigen based vaccine. • U.S. Patent No. 12,059,459: entitled, “Therapeutic Anticancer Neoepitope Vaccine.” • Patent Expiration: The 20-year expiration date of this U.S. Patent No. patent is January 5, 2037. 12,059,459 • Re
Slide 13: mRNA oncology vaccine
mRNA oncology vaccine Nykode Therapeutics | Q2 '24 webcast | Non-confidential 13
Slide 14: Nykode's APC targeting technology can leverage mRNA vaccines
Nykode’s APC targeting technology can leverage mRNA vaccines and presents opportunity for platform expansion Targeted delivery via APCs using Nykode’s technology has been shown to induce broader and stronger CD8+ immune responses vs. existing ‘antigen-alone’ approaches. Preclinical studies have demo
Slide 15: The Nykode vaccine elicits stronger T cell responses
The Nykode vaccine elicits stronger T cell responses The Nykode vaccine elicits stronger T cell responses across a range of mRNA-LNP doses single (prime) vaccination prime + boost vaccination C57BL/6 n=5 per group | Vaccination (1ug) on day 0 & 21 | IFN-g fluorospot on day 7 (prime) & 28 (prime + bo
Slide 16: The Nykode vaccine elicits broader T cell responses biased toward CD8+
The Nykode vaccine elicits broader T cell responses that are biased toward cytotoxic CD8+ T cells Nykode vaccine targets more neoantigens Induction of Cytotoxic CD8+ T Cells prime + boost vaccination 1ug dose 40000 N01 Number of neoantigen responses N02 16 35000 N03 +6 +6 IFNγ SFU/million cells N04
Slide 17: The Nykode vaccine provides superior tumor control
The Nykode vaccine provides superior tumor control The Nykode vaccine led to efficient tumor rejection, slowed tumor growth, and increased survival Average Tumor Volume (mm3) 2000 Control Nykode Control Nykode Antigen Tumor Volume (mm3) 1500 Antigen 2000 2000 2000 1500 1500 1500 1000 1000 1000 1000
Slide 18: Autoimmunity platform update
Autoimmunity platform update Nykode Therapeutics | Q2 '24 webcast | Non-confidential 18
Slide 19: Induction of antigen specific tolerance by targeting tolerogenic APCs
Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs MECHANISM OF ACTION – TOLERANCE INDUCTION (INVERSE VACCINATION) Cells transfected with Effector DNA plasmid B cell vaccine Tol CD4+ Treg APC CD4+ Treg Tol APC Effector Effector T cell T
Slide 20: Nykode vaccine delivers early therapeutic disease protection
Nykode vaccine deliver early therapeutic disease protection, in contrast to equimolar dose of antigen peptide alone EAE MODEL – EARLY THERAPEUTIC DELIVERY TV004 Paralysis 50 ✱✱ 6 TV004 30 µg 40 MOG TV004 3 µg AUC (5-15) (27-63) 5 MOG(27-63) 3 µg 30 PBS EAE score 4 20 Daily clinical scores (5-28) 3 1
Slide 21: Vaccine targeting different APC receptors is effective as early therapeutic in EAE
Nykode vaccine targeting different receptors on APCs is effective as early therapeutic in EAE Target 1 EAE MODEL – EARLY THERAPEUTIC DELIVERY TV004 TV036 Target 1 Target 2 Tol APC Paralysis ✱✱✱ MOG MOG 5 TV004 ✱✱ (27-63) (27-63) Target 2 TV036 50 4 PBS 40 EAE score AUC (5-20) 3 30 2 Daily clinical s
Slide 22: Recent autoimmunity updates substantiate potential of APC-targeted platform
Recent autoimmunity updates further substantiate the potential of Nykode’s APC-targeted platform • New data highlight the versatility and effectiveness of Nykode’s APC-targeting technology within the broad field of immune tolerance • Efficacy in therapeutic setting with two different APC-targeting u
Slide 23: Q2 2024 Financial Results
Q2 2024 Financial Results
Slide 24: Income Statement
Income Statement Revenue from contracts with customers Amounts in USD ‘000 Q2 2024 Q2 2023 YTD 2024 YTD 2023 • R&D activities under Genentech and Regeneron Revenue from contracts with customers 544 5,000 1,371 8,126 agreements Other income 40 100 229 281 • $0.5m (Q2 2024) and $1.2m (H1 2024) under T
Slide 25: Balance Sheet
Balance Sheet Cash and cash equivalents Amounts in USD ‘000 30/06/2024 31/12/2023 • Strong cash position of $136.5m at June 30, 2024 ASSETS Non-current assets Other non-current receivables Property, plant and equipment 4,058 4,413 • Mainly reflects the NOK 325 million payment to the Right-of-use ass
Slide 26: Balance Sheet - contd.
Balance Sheet - contd. Amounts in USD ’0008 31/03/2024 31/12/2023 Equity EQUITY AND LIABILITIES • Total equity of $152m as per June 30, 2024 Equity Share capital 367 367 • Equity ratio of 85% Share premium 128,986 128,986 Other capital reserves 18,043 15,395 Other components of equity (3,044) (3,048
Slide 27: Upcoming milestones
Upcoming milestones Q1 ‘24 VB10.16 Cervical Cancer Updated survival data from VB-C-02 Phase 2 trial Oncology 2H ‘24 VB10.16 Recommended Phase 2 dose in PD-L1+ patients with 1st line Head and Neck Cancer recurrent/metastatic advanced head and neck cancer Autoimmunity 1H ‘24 Update on Nykode’s inver
Slide 28: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Alexandra Deschner Head of Investor Relations IR@nykode.com Nykode Therapeutics | Q2 '24 webcast | Non-confidential
Nykode Therapeutics As — Q2 2024 Earnings Presentation on 6ix